This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
The study also met all secondary endpoints with a reduction in severity of VMS at weeks 4 and 12, a reduction in frequency of VMS at week 1 as well as improvements in sleep disturbances and menopause related quality of life
The transaction is expected to result in approximately $175 million to support further development of IMG-007
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Final decision from the European Commission is anticipated within the coming months
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
